• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伊朗伊斯法罕扎赫拉医院胃肠科针对腹泻型肠易激综合征患者开展的阿奇霉素治疗与非阿奇霉素治疗对比研究。

The comparison of treatments with and without azithromycin in irritable bowel syndrome with diarrhea-predominant in gastrointestinal Clinic of Al-Zahra Hospital, Isfahan, Iran.

作者信息

Yazdani Mohamadreza, Aramesh Amirhossein, Rafiei Rahmatollah, Daghaghzadeh Hamed, Adibi Peyman

机构信息

Department of Infectious Disease, Isfahan University of Medical Sciences, Isfahan, Iran.

Department of Internal Medicine, School of Medicine, Islamic University, Najafabad Branch, Isfahan, Iran.

出版信息

Adv Biomed Res. 2016 Nov 28;5:188. doi: 10.4103/2277-9175.192737. eCollection 2016.

DOI:10.4103/2277-9175.192737
PMID:28028528
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5156970/
Abstract

BACKGROUND

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder. Recent studies suggest the importance of gut flora in the pathophysiology of it. Therefore, antibiotics have demonstrated a substantial benefit to reduce gut flora. Having few side effects, and applying one-dose per day, we studied the effect of azithromycin to treat IBS.

MATERIALS AND METHODS

One hundred and twenty-six patients enrolled a randomized, double-blind, placebo-controlled study. The treatment group received azithromycin in addition to common treatment. Patients were followed for 12 weeks. Patients completed daily diaries documenting their symptoms.

RESULTS

One hundred and thirteen patients completed the study. The onset of relief occurred significantly sooner, and duration of relief was significantly longer in azithromycin group. Movement, abdominal pain, bloating, and gas were significantly better in azithromycin group. Monthly results showed superior relief in bloating, gas, overall symptom, and overall bloating during 3 months. Significantly more patients in azithromycin group felt relief in bloating and gas and had greater consistency relief in almost all weeks.

CONCLUSION

In our study, azithromycin significantly relieved most symptoms, such as abdominal pain, bloating, and gas. Overall symptom and overall bloating were relieved significantly in more patients in the intervention group in all weeks.

摘要

背景

肠易激综合征(IBS)是一种常见的胃肠道疾病。最近的研究表明肠道菌群在其病理生理学中具有重要意义。因此,抗生素已被证明对减少肠道菌群有显著益处。由于副作用少且每日服用一剂,我们研究了阿奇霉素治疗IBS的效果。

材料与方法

126例患者参加了一项随机、双盲、安慰剂对照研究。治疗组在常规治疗的基础上接受阿奇霉素治疗。对患者进行了12周的随访。患者完成每日症状记录日记。

结果

113例患者完成了研究。阿奇霉素组症状缓解的起效时间明显更早,缓解持续时间明显更长。阿奇霉素组的排便、腹痛、腹胀和气体症状明显改善。月度结果显示,在3个月内,阿奇霉素组在腹胀、气体、总体症状和总体腹胀方面的缓解效果更好。阿奇霉素组中,明显更多的患者在腹胀和气体方面感到缓解,并且在几乎所有周内缓解的一致性更高。

结论

在我们的研究中,阿奇霉素显著缓解了大多数症状,如腹痛、腹胀和气体。在所有周内,干预组中更多患者的总体症状和总体腹胀得到了显著缓解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec8b/5156970/ca5c472667e7/ABR-5-188-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec8b/5156970/ca5c472667e7/ABR-5-188-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec8b/5156970/ca5c472667e7/ABR-5-188-g001.jpg

相似文献

1
The comparison of treatments with and without azithromycin in irritable bowel syndrome with diarrhea-predominant in gastrointestinal Clinic of Al-Zahra Hospital, Isfahan, Iran.伊朗伊斯法罕扎赫拉医院胃肠科针对腹泻型肠易激综合征患者开展的阿奇霉素治疗与非阿奇霉素治疗对比研究。
Adv Biomed Res. 2016 Nov 28;5:188. doi: 10.4103/2277-9175.192737. eCollection 2016.
2
Rifaximin therapy for patients with irritable bowel syndrome without constipation.利福昔明治疗无便秘型肠易激综合征患者。
N Engl J Med. 2011 Jan 6;364(1):22-32. doi: 10.1056/NEJMoa1004409.
3
Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points.利福昔明治疗腹泻型肠易激综合征的单个及多个症状:使用新终点的分析。
Clin Ther. 2023 Mar;45(3):198-209. doi: 10.1016/j.clinthera.2023.01.010. Epub 2023 Mar 14.
4
Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial.粪便微生物群移植可减轻部分以腹胀为主的肠易激综合征患者的症状:一项安慰剂对照随机试验的短期和长期结果
Gastroenterology. 2021 Jan;160(1):145-157.e8. doi: 10.1053/j.gastro.2020.07.013. Epub 2020 Jul 15.
5
Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.替加色罗用于治疗肠易激综合征和慢性便秘。
Cochrane Database Syst Rev. 2007 Oct 17(4):CD003960. doi: 10.1002/14651858.CD003960.pub3.
6
Safety and efficacy of purified clinoptilolite-tuff treatment in patients with irritable bowel syndrome with diarrhea: Randomized controlled trial.富含纤维的斜发沸石治疗腹泻型肠易激综合征患者的安全性和有效性:随机对照试验。
World J Gastroenterol. 2022 Dec 14;28(46):6573-6588. doi: 10.3748/wjg.v28.i46.6573.
7
A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome.一项关于益生菌VSL#3对腹泻型肠易激综合征肠道转运及症状影响的随机对照试验。
Aliment Pharmacol Ther. 2003 Apr 1;17(7):895-904. doi: 10.1046/j.1365-2036.2003.01543.x.
8
A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.阿洛司琼治疗腹泻型肠易激综合征男性患者疗效与安全性的剂量范围Ⅱ期研究
Am J Gastroenterol. 2005 Jan;100(1):115-23. doi: 10.1111/j.1572-0241.2005.40365.x.
9
A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.5-羟色胺3型受体拮抗剂阿洛司琼治疗腹泻型肠易激综合征女性患者的一项随机对照临床试验
Arch Intern Med. 2001 Jul 23;161(14):1733-40. doi: 10.1001/archinte.161.14.1733.
10
A Tritordeum-Based Diet for Female Patients with Diarrhea-Predominant Irritable Bowel Syndrome: Effects on Abdominal Bloating and Psychological Symptoms.以三捻橄榄为基础的饮食用于腹泻型肠易激综合征女性患者:对腹胀和心理症状的影响。
Nutrients. 2023 Mar 10;15(6):1361. doi: 10.3390/nu15061361.

本文引用的文献

1
Epidemiological features of irritable bowel syndrome and its subtypes among Iranian adults.伊朗成年人肠易激综合征及其亚型的流行病学特征
Ann Gastroenterol. 2015 Apr-Jun;28(2):253-258.
2
Emerging drug for diarrhea predominant irritable bowel syndrome.用于腹泻型肠易激综合征的新型药物。
Expert Opin Emerg Drugs. 2015 Jun;20(2):247-61. doi: 10.1517/14728214.2015.1013935. Epub 2015 Mar 3.
3
Small bowel bacterial overgrowth in patients with irritable bowel syndrome: the first study in iran.肠易激综合征患者的小肠细菌过度生长:伊朗的第一项研究。
Middle East J Dig Dis. 2015 Jan;7(1):36-40.
4
Symptom pattern following a meal challenge test in patients with irritable bowel syndrome and healthy controls.肠易激综合征患者和健康对照者餐后挑战试验后的症状模式。
United European Gastroenterol J. 2013 Oct;1(5):358-67. doi: 10.1177/2050640613501817.
5
Rifaximin therapy of irritable bowel syndrome.利福昔明治疗肠易激综合征
Clin Med Insights Gastroenterol. 2012 Jun 25;5:31-41. doi: 10.4137/CGast.S7382. eCollection 2012.
6
Irritable bowel syndrome: the evolution of multi-dimensional looking and multidisciplinary treatments.肠易激综合征:多维度观察与多学科治疗的进展
World J Gastroenterol. 2014 Mar 14;20(10):2499-514. doi: 10.3748/wjg.v20.i10.2499.
7
Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype.肠易激综合征与小肠细菌过度生长:是有意义的关联还是不必要的炒作。
World J Gastroenterol. 2014 Mar 14;20(10):2482-91. doi: 10.3748/wjg.v20.i10.2482.
8
A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea.一项针对伴有腹泻的肠易激综合征患者的昂丹司琼治疗的随机试验。
Gut. 2014 Oct;63(10):1617-25. doi: 10.1136/gutjnl-2013-305989. Epub 2013 Dec 12.
9
Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome.腹泻型肠易激综合征的当前和未来药物治疗。
Expert Opin Pharmacother. 2013 Jun;14(9):1151-60. doi: 10.1517/14656566.2013.794223. Epub 2013 Apr 27.
10
Rifaximin in irritable bowel syndrome: rationale, evidence and clinical use.利福昔明在肠易激综合征中的应用:原理、证据与临床实践。
Ther Adv Chronic Dis. 2013 Mar;4(2):71-5. doi: 10.1177/2040622312472008.